Key result
TTVI reduces all-cause mortality ~30% versus OMT in pooled analyses but lacks RCT confirmation.
Why the study?
Severe symptomatic TR carries a poor prognosis with high surgical ineligibility, and the impact of TTVI on clinical outcomes compared with OMT remains uncertain.
Does transcatheter tricuspid valve intervention reduce mortality and adverse clinical events compared with optimal medical therapy in patients with severe symptomatic tricuspid regurgitation?
Meta-Analysis (n=6,732)
Does transcatheter tricuspid valve intervention reduce mortality and adverse clinical events compared with optimal medical therapy in patients with severe symptomatic tricuspid regurgitation?
Answers are grounded in this paper and cite their sources.
TTVI is associated with reduced all-cause mortality in symptomatic TR when pooling observational and randomized data, but the lack of benefit in RCT-only analyses highlights the need for cautious interpretation due to potential confounding.
BACKGROUND: Severe symptomatic tricuspid regurgitation (TR) is associated with a poor prognosis, and many patients are ineligible for surgical intervention. Transcatheter tricuspid valve intervention (TTVI) has emerged as a less invasive alternative, but its impact on clinical outcomes compared with optimal medical therapy (OMT) remains uncertain. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies comparing TTVI (transcatheter edge-to-edge repair or valve replacement) with OMT. Databases were searched from inception through December 31, 2025. Outcomes included all-cause and cardiovascular mortality, heart failure (HF) hospitalization, myocardial infarction, stroke, bleeding, and new permanent pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation. Random-effects models were used to calculate pooled odds ratios (ORs). RESULTS: Thirteen studies encompassing 6732 patients (3240 TTVI; 3492 OMT) were included. In pooled analyses of randomized and observational studies, TTVI was associated with a significant reduction in all-cause mortality compared with OMT (OR 0.70; p=0.009). However, this benefit was not observed in an RCT-only analysis. No significant differences were noted in cardiovascular mortality, HF hospitalization, myocardial infarction, severe bleeding, or stroke. A non-significant trend toward increased PPM/ICD implantation (p=0.06) was primarily driven by valve replacement devices. CONCLUSIONS: In symptomatic TR, TTVI was associated with reduced all-cause mortality in pooled analyses incorporating both randomized and observational data; however, this benefit was not confirmed in RCT-only analyses, likely reflecting residual confounding in non-randomized studies which may overestimate treatment effects. These findings support TTVI as an effective therapeutic option for appropriately selected high-risk patients.
No takes yet. Share an insight, caveat, or question.
Banga et al. (2026) conducted a meta-analysis in Symptomatic tricuspid regurgitation (n=6,732). Transcatheter tricuspid valve intervention (TTVI) vs. Optimal medical therapy (OMT) was evaluated on All-cause mortality (OR 0.70, p=0.009). Transcatheter tricuspid valve intervention reduced all-cause mortality compared with optimal medical therapy in pooled analyses, but this was not confirmed in RCT-only analyses.
Synapse has enriched 10 related papers. Consider them for comparative context: